STL Index for: Cordoro M. Kelly

The Evolving Role of Biologics in the Treatment of Pediatric Psoriasis

The exact role of biologics in the treatment of pediatric psoriasis remains undefined but evolving. This article will provide a summary of the cumulative pediatric safety and efficacy data for the anti-tumor necrosis factor-alpha (TNF-α) agents and interleukin (IL)-12 and IL-23 (IL12/23) pathway inhibitor.

Systemic and Light Therapies for the Management of Childhood Psoriasis: Part II

The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, and severity. Part II of this 2-part series features an overview of systemic and light therapies including their varying degrees of effectiveness, potential side-effects and applications in clinical practice.

Topical Therapy for the Management of Childhood Psoriasis: Part I

Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. Part I of this 2-part series will focus on topical agents, their varying degrees of effectiveness, potential side-effects and applications in clinical practice.

TNF-a Inhibitors in Dermatology

To date, the US FDA has approved three tumor necrosis factor (TNF)-a inhibitors for use in dermatology. The distinct and targeted mechanism of action of the TNF inhibitors allows dermatologists to customize therapy to match the individual needs and characteristics of patients who are candidates for systemic therapy.

POPULAR

Advertisement